hen caring for our patients with pulmonary arterial hypertension (PAH), how many times have we wondered, could this patient really have pulmonary veno-occlusive disease/pulmonary capillary hemangiomiatosis (PVOD/ PCH)? This question typically arises if there is a suggestive computed tomography scan, a low diffusing capacity of the lungs for carbon monoxide, substantial hypoxemia, or, certainly, a poor response to PAH-specific medications or development of pulmonary edema (PVOD/PCH versus unsuspected diastolic dysfunction). In fact, we recently were referred such a patient: the computed tomography scan showed septal thickening and lymphadenopathy, the diffusing capacity of the lungs for carbon monoxide was low, hypoxia requiring 8 to 10 L of supplemental oxygen was present, and marked clinical deterioration occurred after being started on PAH therapy with ambrisentan and tadalafil. Ultimately, the patient underwent lung biopsy to prove what we were certain was PVOD/PCH. To our surprise, histologically, there was no venous involvement, and she was diagnosed with idiopathic PAH (IPAH). However, based on the study by Hadinnapola and colleagues in this issue of Circulation, 1 which found significant overlap in clinical, radiological, and in 1 case even histological findings, could she still have had EIF2AK4 mutations and thus PVOD/PCH genetically?
with IPAH and PVOD/PCH than we clinically suspect. As such, genetic testing may be more important and relevant than we had previously thought and could have a substantial impact on therapeutic decisions.
That said, like any interesting study, this study raises more clinical questions and uncertainties than answers, and our ability to answer these questions can be either enhanced or challenged by the methodological choices in the study.
Clinically, there are several questions: (1) Is PVOD/ PCH more common than we think? (2) Do biallelic EI-F2AK4 mutations in a patient presumed to have IPAH portend a uniformly poor outcome as would be expected in PVOD/PCH? (3) What should the clinician do with this information?
IS PVOD/PCH MORE COMMON THAN WE THINK?
In the REVEAL study (Registry to Evaluate Early and Long-Term PAH Disease Management; not Randomized Evaluation of the Effects of Anecetrapib Through Lipid Modification), the largest PAH registry thus far (3 500 patients), the percentage of patients with a clinical diagnosis of PVOD/PCH was ≈0.5%. 3 However, REVEAL included all subgroups of PAH; as such, the percentage of patients with PVOD/PCH may have been diluted. In the current study, in which the overwhelming majority of patients had IPAH or heritable PAH, 1.5% of all patients had biallelic EIF2AK4 mutations and thus genetic PVOD/PCH. Because only 25% to 30% of patients with PVOD/PCH carry these mutations, 4 this figure may be an underestimate and suggests that this entity may be more common than we think. This finding is important because of the lack of viable treatment options in PVOD/PCH, except for lung transplantation. The authors should also be applauded for including a cohort of patients without pulmonary hypertension. The analysis demonstrating that the EIF2AK4 allele is overrepresented among patients with IPAH versus controls (1.2% versus 0.5%, P=0.03) is essential for the conclusion that some of the patients with IPAH may have PVOD/PCH. Larger samples may determine which specific variants are of critical concern.
DO BIALLELIC EIF2AK4 MUTATIONS IN A PATIENT WITH PRESUMED IPAH PORTEND A UNIFORMLY POOR OUTCOME AS WOULD BE EXPECTED IN PVOD/PCH?
Patients with PVOD/PCH have a much poorer and often a deleterious response to PAH-specific therapies, and lung transplantation is thought to be their only viable option. In a recent cohort of patients with PVOD/ PCH, 4 the probability of event-free survival, defined as death or transplantation, at 1 and 3 years was 63% and 32% in carriers of biallelic EIF2AK4 mutations versus 75% and 34% in noncarriers, respectively. In the current study, patients with PAH with biallelic EIF2AK4 mutations had a 3-year survival rate of >75%. However, a direct comparison with these earlier studies is impossible, particularly because the primary survival analysis mixed prevalent and newly diagnosed patients without accounting for left truncation. This could lead to an overestimation of survival time for the prevalent patients because the time at risk for an event began only after enrollment, and including the time between diagnosis and enrollment leads to immortal time bias.
Some uncertainty exists regarding response to therapy in the patients classified as IPAH who were found to have biallelic EIF2AK4 mutations. Was it what would be expected in a patient with PVOD/PCH or was it more like that expected in a patient with IPAH? In other words, is the response to therapy driven by the phenotype or genotype? The authors note that patients with a clinical diagnosis of IPAH and biallelic EIF2AK4 mutations treated with PAH-specific therapies did not improve their functional class at either 1 or 3 years after diagnosis as did the other PAH groups (Table X in the online-only Data Supplement for the article by Morrell et al. 1 ) However, significant data were missing during later follow-up. Had these patients been transplanted or lost or had they died? In future studies, use of a composite end point of survival, free from transplant or major clinical worsening, may clarify this point. If the shortterm response is at least similar to that of patients with IPAH, early referral for transplant may not be as crucial, and a trial of medical therapies might be considered.
WHAT SHOULD THE CLINICIAN DO WITH THIS INFORMATION?
Ultimately, that is the most important question if we are to use this information to help the patient with PAH and improve care. Further underlying the complexity of this issue is the 1 patient in the study in whom tissue was available. The clinical phenotype suggested IPAH, the genetic analysis suggested PVOD/PCH, and the histology was more consistent with IPAH, in that the pathology was predominantly precapillary. To make this situation even more difficult, overlaps occurred in the radiological characteristics of the patients examined. No pattern was sensitive or specific for PVOD/PCH. Thus, the genotype-phenotype relationships of these patients may be much more complex and less clear than expected. Yet the outcome among the patients with biallelic EIF2AK4 mutations was generally poorer. As such, should a clinician treat the phenotype or genotype? Based on these data and our current clinical understanding of this entity, we cannot yet be certain.
However, this study is thought-provoking and has opened a new door in potential research and clinical studies that will hopefully lead to clarity on these questions.
Oh, and our patient: she has had an exceptional hemodynamic and clinical response to intravenous epoprostenol. We assume she had IPAH after all (at least phenotypically).
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